Fibrolamellar hepatocellular carcinoma: An epidemiologic and 5-year cancer survival assessment based off SEER data - 11/08/23
, Khalid Ahmed a, Udit Asija a, Elmkdad Mohammed a, Anthony Iskander b, Niraj James Shah c, Hemant Goyal a, Vikas Khurana a, Nasr Simin a, Ganesh Aswath d, Savio John dHighlights |
• | Fibrolamellar hepatocellular (HCC) carcinoma is a rare subset of liver tumors. |
• | Risks factors and symptoms can vary greatly from classic HCC. |
• | Younger age, male gender, white race seemed to confer survival advantage. |
• | For surgical candidates, those who underwent lymph node and wedge resection seemed to have the best long term outcomes. |
• | For non-surgical candidates, those who underwent chemotherapy had better outcomes. |
Abstract |
The fibrolamellar variant of hepatocellular carcinoma makes up a small percentage of liver tumors. Despite being a subset, it has been noted in the literature to have variations in terms of its epidemiology and intervention recommendations. Using the Surveillance, Epidemiology, and End Results database, 339 cases from 1988 to 2016 were studied. Favorable prognostic epidemiological factors included male sex, younger ages, and white race. Those who underwent any lymph node resection (combined with liver resection) did better than those without lymph node resection; chemotherapy proved beneficial for those where surgery was contraindicated. To our knowledge, this report is the largest conglomerate dataset analyzing prognostic profiles and treatment strategies for fibrolamellar hepatocellular carcinoma.
El texto completo de este artículo está disponible en PDF.Esquema
Vol 47 - N° 7
Artículo 102162- août 2023 Regresar al número
Artículo precedente
- Serum cell division cycle 42 in advanced hepatocellular carcinoma patients: Linkage with clinical characteristics and immune checkpoint inhibitor-related treatment outcomes
- Jinxia Xu, Ruiyu Shao, Xiaoru Zhang, Deshun Yao, Sugui Han
- Genomic characterization of early-stage hepatocellular carcinoma patients with Hepatitis B using circulating tumor DNA
- Daniel Lin, Rui Luo, Zhong Ye, Qiang Wei, Ho Bae, Hee-soon Juon, Hie Won Hann, James Posey, Chun Wang
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?